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A B S T R A C T   
Bovine colostrum is a rich source of nutrients and biologically active molecules known to be able to modulate the 
human immune system, such as lactoferrin, lysozyme, lactoperoxidase, immunoglobulins and growth factors. 
This comprehensive review aimed to gather evidence from animal experimentation and clinical trials that 
investigated the potential effects of bovine colostrum in preventing and treating diseases that affect the human 
gastrointestinal tract. Considered safe for human consumption, BC or its isolate components were used against a 
range of different gastrointestinal disorders. Beneficial effects were observed in several conditions: gastrointes-
tinal infections, infectious diarrhoea, drug-induced lesions, gut-barrier malfunction, and inflammatory bowel 
disease. Under proper processing to maintain its components' integrity, BC products are valuable supplements 
with high nutraceutical value, capable of promoting and restoring gastrointestinal health.   
1. Introduction 
Bovine colostrum (BC) is the first milk secretion of the mammary 
gland of cows after calving. It is rich in immunoglobulins, lactoferrin, 
lysozyme, lactoperoxidase, growth factors and bioactive peptides. 
Colostrum has higher levels of protein, fat, vitamins, and minerals when 
compared to milk. This compositional singularity of colostrum enables 
full development of the newborn calf, in addition to guaranteeing im-
munity against several pathogens [1–4]. 
A healthy cow produces approximately 5 to 10 L of colostrum per 
milking [5], an amount that usually exceeds the requirements of the 
newborn calf. Therefore, its surplus can be used in producing food, 
supplements, or medicines. However, special care must be given to its 
storage and processing so as not to compromise the biological activity of 
its components and consequently its therapeutic effect [6]. The dairy 
industries do not commercially exploit colostrum on a large scale due to 
processing and storage problems, such as its low coagulation tempera-
ture, which affects pasteurization [1,7]. Apparently, most BC metabo-
lites' concentration is preserved or mildly affected if a gentle heat 
treatment procedure is applied (60 ◦C, 25–30 min pasteurization) [8,9]. 
Even though heat treatment can compromise bioactive proteins due to 
denaturation, their abundance in BC is sufficient to exert beneficial ef-
fects [7,10]. Most of the commercially available BC products on the 
market are prepared by freeze-drying or spray drying, aiming to main-
tain the biological activity of its components [11–15]. These products 
are often ready for consumption and made up of mixtures with 
skimmed-milk powder, whey powder, and whole milk [1,4]. 
BC is reported as safe for human consumption. There are no 
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contraindications regarding high dose intake and few side effects of 
clinical relevance have been registered [16,17]. Due to its composition, 
BC consumption is being encouraged as a nutritional supplement for 
newborns, children, and adults who have no restrictions on bovine milk 
consumption [18]. An increasing number of clinical trials gather sig-
nificant results that advocate in favour of the use of bovine colostrum as 
a nutraceutical food or supplement (e.g. https://trialbulletin.com/lib 
/trials/term=Colostrum). Its beneficial effects on prophylaxis and 
treatment of gastrointestinal disorders (Fig. 1) are mainly related to the 
numerous immunomodulating components, which maintain and 
recover gastrointestinal tract health [19]. Several studies indicate that 
colostrum consumption can reduce the occurrence and severity of 
digestive disorders such as diarrhoea and alleviate inflammatory bowel 
disease. It can also contribute to preventing and treating colon problems, 
short bowel syndrome and constipation [4,16,20–22]. Furthermore, 
there is evidence showing the relationship between the immune re-
sponses triggered in the intestine by BC supplementation and the im-
munity of the respiratory system [23]. 
This review presents the main scientific evidence on the effects of 
bovine colostrum supplementation on preventing and treating human 
gastrointestinal tract diseases and symptoms. 
2. Chemical composition of bovine colostrum 
As the first milk secreted by female mammals to nourish their 
offspring after delivery, colostrum is responsible not only for supplying 
nutrients, but also antibacterial substances and growth factors [2]. It 
provides the newborn with immunological protection against pathogens 
and plays an essential role in their physiology, directly influencing their 
growth and development. Colostrum composition differs from that of 
mature milk especially due to the presence of immunological and bio-
logically active components (including immunoglobulins, leukocytes, 
lactoferrin, lysozyme, cytokines, growth factors, hormones, and oligo-
saccharides), thereby making it a product of great interest for utilization 
by the pharmaceutical and food industries [1,4]. 
The rich composition of BC propels its use in human nutrition as a 
source of bioactive components potentially capable of promoting health 
improvements by preventing and treating several diseases (Fig. 2) 
[23–25]. It has already been used in desserts, beverages, and as a food 
supplement in some countries [20]. It is available on the market as 
tablets, powder, concentrate, capsules, chewing gum, milk supple-
mented with colostrum, ice cream, curd, yoghurt, and milk beverages 
with colostrum added, among other products [26–29]. It is worthy of 
mentioning that there is great variability in the bioactivity of worldwide 
commercially available BC products [15]. 
BC chemical constituents can be divided into three main categories: 
nutritional components, immune factors, and growth factors. Nutri-
tional components include the well-known macro and micronutrients 
present in milk (proteins, lipids, sugars, vitamins, and minerals). Im-
munoglobulins (IgA, IgG, and IgM), lactoferrin, lysozyme and lacto-
peroxidase are the immune factors. Within the growth factors, there are 
epidermal growth factor (EGF), fibroblast growth factors (FGF1 and 
FGF2), insulin-like growth factors (IGF-I and IGF-II), transforming 
growth factors beta (TGF-b1 and TGF-b2), platelet-derived growth fac-
tor (PDGF) and betacellulin (BTC) [12,30]. Table 1 shows the nutrients 
and bioactive compounds present in bovine colostrum. 
The nutritional composition of colostrum varies according to the 
breed, calving order, feeding and health status of the cow. Furthermore, 
the postpartum time also directly influences its composition, especially 
when we compare the colostrum collected in the first postpartum hours 
with that obtained in subsequent milkings (usually referred to as tran-
sition milk), as well as with mature milk (Table 2) [31,33,34]. 
2.1. Bovine colostrum immune factors 
2.1.1. Immunoglobulins 
Immunoglobulins G (IgG), A (IgA) and M (IgM) are present in bovine 
colostrum. They are found in high concentrations in colostrum, which 
contributes to its high protein content in BC. IgG corresponds to about 
80% of the total amount of immunoglobulins [16,35,36]. The primary 
function of immunoglobulins is to provide passive immunity to the calf 
once, except for IgG, maternal immunoglobulins in cattle cannot cross 
the placental barrier to the fetus [37]. 
Immunoglobulins are well known for their benefits to human health 
in terms of the immunogenic response. When hosts are exposed to 
foreign bodies (antigens), these antibodies bind, recognise, and destroy 
bacteria, toxins, viruses, and other antigens. The immunoglobulins 
levels in bovine colostrum are about 100 times higher than those found 
in mature milk [38,39]. 
2.1.2. Lactoferrin 
Lactoferrin is an iron-binding glycoprotein present in body secretions 
such as tears, sweat, semen, saliva, and colostrum. Like the other im-
mune components of BC, its concentration decreases over the hours after 
delivery and is present in a lower concentration in mature milk. The 
lactoferrin concentration in BC and mature milk generally varies be-
tween 1.5 and 5 mg/mL and 0.02–0.75 mg/mL, respectively [31]. 
Lactoferrin displays important activities, such as antioxidant, anti-
microbial and immunomodulatory. Moreover, it increases the prolifer-
ation and differentiation of intestinal epithelial cells. Thus, lactoferrin 
constitutes a vital role in the innate immune system [40,41]. Research 
has shown that lactoferrin has a high resistance rate to digestion, and 
promotes benefits to children's intestinal health by reducing the patho-
genic microbial load [42]. The biological activities of lactoferrin are 
related to its basic N-terminal domain, which interacts with various 
microbial and host targets [43]. 
2.1.3. Lysozyme 
Lysozyme is an antimicrobial enzyme present in milk, colostrum, and 
other bodily secretions. It hydrolyses the peptidoglycan layer of the 
bacterial cell wall, causing the lysis of gram-positive and gram-negative 
bacterial cells. Lysozyme concentration is higher in colostrum than in 
milk, varying between 0.14 and 0.7 mg/L and 0.07–0.6 mg/L, respec-
tively [4,16,31]. 
2.1.4. Lactoperoxidase 
Lactoperoxidase (LP) is an enzyme belonging to the peroxidase 
family, which occurs naturally in colostrum and other body secretions. 
Its function is to catalyse the oxidation of thiocyanates. Lactoperoxidase 
catalyses an antimicrobial system from thiocyanate ion (SCN-) and 
Fig. 1. Bovine colostrum components, especially immune and growth factors, 
are related to positive effects on the gastrointestinal tract in different impaired 
conditions. Created with BioRender.com. 
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hydrogen peroxide, generating oxidation products that inhibit bacteria, 
protozoa, and fungi growth. The LP concentration in the colostrum is 
low and increases over the postpartum days, being the enzyme with the 
highest concentration in milk. Usually, LP participates in the body's 
natural defence system [12,16,44]. 
2.2. Bovine colostrum growth factors 
Bovine colostrum contains about 50 polypeptides described as 
growth factors. The main growth factors include epidermal growth 
factor (EGF), betacellulin (BTC), insulin-like growth factor (IGF-1), 
transforming growth factor β1 (TGF-β1), fibroblast growth factor 1 and 2 
(FGF1 and FGF2) and platelet-derived growth factor (PDGF) [31]. These 
polypeptides have multiple functions in the body but are found in low 
concentrations in mature milk, which reinforces the importance of 
evaluating the therapeutic benefits of colostrum. Once most of the 
growth factors present in bovine colostrum appear to resist thermal 
treatments up to 60 ◦C [15], new techniques have been developed for 
their extraction in bovine colostrum and whey [45]. Polypeptides such 
as EGF, IGF-1 and TGF-β1 can be absorbed intact in the gastrointestinal 
tract or partially degraded [35,44,45]. 
BC also contains bioactive peptides, which are encrypted within the 
sequence of their original protein molecule. They can be released as a 
result of lactic acid bacteria and probiotic strains activity, which are 
highly proteolytic and fragment proteins. This release of bioactive 
peptides from colostrum proteins can occur faster during the colostrum 
fermentation process [46,47]. The function of bioactive peptides varies 
according to the length and sequence of amino acids. Some of the 
bioactive peptides found in milk and colostrum have been shown to 
display antihypertensive, antioxidant, antithrombotic, antimicrobial, 
and immunomodulatory functions [44]. 
3. Effects of colostrum on gastrointestinal tract disorders 
Supplementing the human diet with BC modulates immune system 
Fig. 2. Benefits associated with the intake of bovine colostrum or its isolated immunomodulatory components. GI: gastrointestinal; GIT: gastrointestinal tract. Based 
on data synthesized by Galdino et al. [23], Sangild et al. [24], and Arslan et al. [25]. Created with BioRender.com. 
Table 1 
Bovine colostrum chemical composition.  
Carbohydrates Lactose and oligosaccharides 
Proteins Casein, Immunoglobulins (IgG, IgA, and IgM), Lactoferrin 
Lipids Short, medium and long-chain fatty acids, mostly saturated 
Minerals Ca > K > Na > Mg, Zn > Fe 
Vitamins A, E, D, K, C and B complex 
Free amino 
acids 
Lys > Phe > His > Leu > Glu > Ile > Val > Met > Pro 
Cytokines Interleukins, Tumour necrosis factor, Interferon 
Growth Factors Epidermal growth factor (EGF), Betacellulin (BTC), Insulin-like 
growth factor (IGF-1), Transforming growth factor β1 (TGF-β1), 
fibroblast growth factor 1 and 2 (FGF1 and FGF2), platelet- 
derived growth factor (PDGF) 
Enzymes Lactoperoxidase, Lysozyme, Proteinases, Lipases, Esterases 
Adapted from Buttar et al. [18], McGrath et al. [31] and Bartkiene et al. [32]. 
Table 2 
Compositional differences between bovine colostrum and mature milk.  
Constituents (%) Colostrum* Mature milk 
Lactose 2.7 5.0 
Fat 6.7 4.0 
Protein 14.0 3.1 
Casein 4.8 2.5 
Ash 1.11 0.74 
Total solids 23.9 12.9 
Solids-not-fat 16.7 8.8 
Adapted from Borad & Singh [12]. 
* First postpartum milking. 
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responses, improving symptoms of diseases that affect the gastrointes-
tinal tract (GIT). Recent research has demonstrated beneficial effects of 
BC components against various gastrointestinal disorders, especially on 
inflammation, treating or preventing secondary ulceration and diar-
rhoea caused by viruses [16,48–50]. Apparently, the anti-inflammatory 
activity of BC in intestinal epithelial cells is related to the suppression of 
nuclear factor-κB expression [51]. GIT health benefits related to whole 
BC or isolate components supplementation are summarised in Table 3. 
BC can also be used as adjunctive therapy to alleviate side effects 
caused by drugs, where the gastrointestinal tract suffers injuries and is 
weakened due to pharmacological therapies. BC was able to reduce 
inflammation of oral and intestinal mucosa caused by cancer treatments 
[4,16,18]. 
Another promising application of BC supplementation is in children 
with autism spectrum disorders (ASD). They are prone to gastrointes-
tinal disorders such as diarrhoea, irritable bowel syndrome and bacterial 
dysbiosis. Sanctuary et al. studied the effects of BC and BC combined 
with a probiotic strain supplementation in a pilot study with children 
with ASD [52]. In this 10-week double-blind, crossover, randomised 
intervention, there was an improvement in chronic gastrointestinal 
symptoms such as pain with stooling, frequency of diarrhoea and stool 
consistency. However, larger trials, preferably placebo-controlled, are 
needed to determine the efficacy of these treatments. 
3.1. Gastrointestinal infections 
Yadav and co-workers tested BC antimicrobial and anti- 
inflammatory activity in rats underwent induced edema [86]. Colos-
trum reduced the growth of five bacteria strains (Escherichia coli, 
Staphylococcus aureus, Proteus vulgaris, Enterobacter aerogenes and Sal-
monella typhi) and edema. In another study, bovine colostrum proved to 
be effective in reducing enterotoxigenic E. coli colonization and was also 
able to modulate the intestinal immune system of piglets when 
compared to a group fed with a milk replacer [54]. BC can also be used 
to reduce uropathogenesis caused by the gastrointestinal carriage of 
E. coli, as demonstrated by Larcombe et al. [53]. These authors used 
hyperimmune colostrum as a therapy against E. coli in mice, resulting in 
interruption of gastrointestinal colonization. The product called “hy-
perimmune colostrum” is obtained through cows' immunization with 
the microbial strains of interest, resulting in colostrum with specific 
antibodies [87]. A Clostridium difficile toxin–specific hyperimmune 
bovine colostrum was effective against C. difficile infection (CDI) in 
piglets. Liquid and freeze-dried hyperimmune colostrum are suggested 
to be used as immunoglobulin-driven treatments to control CDI, as safe, 
affordable and specific antibiotic alternatives which spare the colonic 
microbiota [55]. 
Promising products are being developed and can potentially be used 
as functional foods, helping to prevent gastrointestinal infections [88]. 
Bartkiene and co-workers evaluated the influence of fermentation with 
Lactobacillues plantarum and Lactobacillus paracasei and different drying 
methods in the amount of IgG, IgA, and IgM in bovine colostrum and 
antimicrobial activity in BC products. The fermented colostrum products 
inhibited the growth of 12 pathogens and showed high IgG and IgM 
content [89]. 
In sepsis cases, the intestinal release of endotoxins by pathogens 
plays an important role in infectious complications [90]. The oral con-
sumption of colostrum is suggested as a prophylactic strategy for sur-
gical patients because it reduces the translocation of gut-derived Gram- 
negative bacterial lipopolysaccharide (LPS, or endotoxin), inhibiting 
enterogenic endotoxemia [91]. In animal experiments, BC and BC 
enriched with lactoferrin had proven to reduce 67% and 80% of the 
plasma levels of endotoxins, respectively [56]. 
A BC commercially available concentrate supplement was success-
fully used in a randomised pilot human study to reduce endotoxin levels 
generated after abdominal surgery, as demonstrated by Bölke et al. [57]. 
In the mentioned study, patients orally received a preparation 
containing colostrum immunoglobulin before surgery to assess the ac-
tion on intra- and post-operative plasma endotoxin levels. The group 
which received the oral BC preparation had significantly lower levels of 
endotoxin and endotoxin-neutralizing capacity. 
3.1.1. Helicobacter pylori infection 
H. pylori is considered one of the most common bacterial infections in 
humans. The infection is caused by oral ingestion of the bacterium, 
transmitted in early childhood; however, its elimination in children can 
be spontaneous [92]. H. pylori infection is highly associated with several 
gastrointestinal disorders, including chronic gastritis, peptic and 
duodenal ulcers, and gastric adenocarcinoma [93]. A consensus report 
published in 2017 recommends treating H. pylori gastritis for all infected 
subjects [94]. The prevalence H. pylori infections are higher in devel-
oping countries and poor socioeconomic conditions [95]. 
Decades ago, an in vitro study showed the ability of colostrum to 
inhibit the binding of H. pylori and Helicobacter mustelae to lipid re-
ceptors [96]. BC concentrate partially inhibited microbial adhesion to 
specific lipids (putative receptors for microbe-host cell membrane 
interaction), demonstrating that colostrum lipids can modulate the 
interaction of H. pylori and other pathogens with envelope adhesins. 
In mouse models, hyperimmune bovine colostrum has successfully 
reduced Helicobacter spp. infections [59]. Mice infected with H. felis 
received hyperimmune colostrum associated with antibiotics after 
infection. Bacterial load reduction was significant when colostrum was 
co-administered with amoxicillin [97]. Tran et al. evaluated four ther-
apies combining hyperimmune colostrum, amoxicillin, zinc and ace-
tylcysteine. The therapies combined with hyperimmune colostrum were 
effective in reducing the H. pylori bacterial load [58]. 
Isolate bovine lactoferrin was tested in a clinical trial [60]. The 
volunteers (50 patients infected with H. pylori) were divided into two 
groups: one group received traditional therapy (clarithromycin, omep-
razole, amoxicillin, or metronidazole), and the other group received 
conventional therapy plus lactoferrin. The addition of lactoferrin to 
conventional treatment improved the H. pylori eradication rate 
compared to the control group (92% versus 68%), showing that lacto-
ferrin can effectively treat infection by this bacterium. 
The studies presented herein have shown that BC and lactoferrin, one 
of its bioactive components, are effective in fighting infection by bac-
teria of the Helicobacter spp. genus. The mechanisms of action of BC 
components against Helicobacter spp. growth require further 
investigation. 
3.2. Infectious diarrhoea 
Diarrhoea is a digestive disorder that can be caused by several 
pathogens, especially E. coli, rotavirus and Cryptosporidium spp. Sup-
plementation with BC has shown action against these pathogens [30], 
and rich evidence has been gathered over the years, confirming its 
benefits. 
The effect of colostrum consumption has been studied in animals 
infected with human pathogens, demonstrating beneficial effects against 
agents which cause diarrhoea. Inagaki et al. developed a study to 
determine the effect of colostrum administration on human rotavirus 
infection in lactating mice [66]. To this end, different doses of skimmed 
and concentrated bovine colostrum were administered, resulting in re-
lief of diarrhoeal symptoms. The authors recommend the use of BC for 
protection against severe rotavirus-induced gastroenteritis for immu-
nocompromised hosts, such as children and older adults. 
Kaducu and co-workers conducted a study to investigate the effects 
of colostrum supplementation on treating HIV-associated diarrhoea 
[65]. A total of 45 patients received 50 g of the commercially available 
colostrum-based food product twice daily for 28 days. There was a sig-
nificant decrease of 79% in the evacuation frequency in patients on the 
colostrum-based supplement at the 4th week compared to the placebo 
group (58% decrease). The reduction in the evacuation frequency was 
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Table 3 
Effects of bovine colostrum or bovine colostrum isolate compounds supplementation on the gastrointestinal tract health observed in animal experimentation and 
human studies.  
Application Studied sample Intervention Main benefits Reference 
Gastrointestinal infections 40 piglets Liquid BC prepared by mixing BC powder with water 
(approximately 150 g of powder in 1 L of water), ad 
libitum for 8 days 
Reduction of enterotoxigenic Escherichia coli 
Modulation of the intestinal mucosal immune 
system 
[53] 
40 weak piglets Commercial skimmed standardised BC product, ad 
libitum for 8 days 
Reduction of the frequency of diarrhoea in 
piglets with incompetent intestinal immune 
system by modulation of the immune response 
Lowering colonization of enterotoxigenic 
E. coli (ETEC F18) in the intestinal tissue 
[54] 
23 piglets 25 mL Hyperimmune bovine colostrum (HBC), twice 
daily for 7 days, oral administration after 
inoculation 
Reduction or absence of diarrhoea in C. difficile 
infected animals 
Preservation of normal human gut microbiota 
[55]  
35 male Wistar 
rats 
400 mg iron saturated BC/kg of different 
compositions; 400 mg type 2 BC/kg plus 80 mg 
bovine iron saturated lactoferrin/kg 
Reduction of both endotoxin activity in plasma 
and bacterial contamination of the peritoneal 
cavity in experimental septic shock 
[56]  
40 patients (22 
male, 18 female) 
56 g of colostral preparation (Lactobin™), for 3 
days, pre-operatively. Daily dose divided into four 
parts (before breakfast, at lunch, at supper, and at 
night rest) 
Reduction of circulating endotoxin levels and 
inhibition of the decrease of plasma endotoxin- 







0.1 mL HBC + N-acetylcysteine + zinc + amoxicillin 
A, twice a day, for 10 days, by oral gavage 
Eradication of H. pylori infection [58] 
100 mice Bovine colostral hyperimmune immunoglobulin 
preparation or immunoglobulins from non- 
immunized animals in concentrations of 0.1, 10 or 
50 mg/mL in the drinking water (around 20 mg/ 
mL), for 10 or 20 days. 
Infection cure rate of 66% 
Reduction of colonies number 
[59] 
50 patients, both 
gender 
Traditional therapy (clarithromycin, omeprazole, 
amoxicillin, or metronidazole) versus traditional 
therapy plus lactoferrin (Pravotin™), for 1 week. 
Orally taken 2 h after break-fast (200 mg) and 2 h 
after dinner (100 mg) 
Improvement of the eradication rate of H. 
pylori 
[60] 
Gut-barrier malfunction 14 patients (6 
male, 8 female) 
100 mL of 10% colostrum solution, orally, twice a 
day, for 4 weeks 
Decrease of intestinal permeability 
Prevention of gastric lesions induced by non- 
steroidal anti-inflammatory drugs 
[61] 
70 patients (35 
male, 35 female) 
BC powder 20 g/ day, three times per day, for 10 
days, enteral nutrition, in ICU patients 
Decrease of intestinal permeability 
Reduction of the incidence of diarrhoea 
[62] 
16 healthy male 
athletes 
500 mg of BC powder, orally, twice daily, for 20 days Decrease of intestinal permeability [63]  
12 healthy male 
athletes 
High-protein BC powder (NZMP™), 20 g/d, orally, 
for 14 days +14-d washout 







BALB/c mice, 5- 
d-old 
Skimmed and concentrated bovine late colostrum 
dissolved in 50 μL of PBS, given orally by gavage, 60 
min before viral inoculation 
A dosage greater than 1.0 mg, 60 min before 
viral inoculation, prevented the development 
of diarrhoea 




87 men 50 g of colostrum-based supplement (powder, orally, 
twice a day for 28 days) 
Decrease of evacuation frequency 
Promotion of weight gain 
[66] 




aged 6 m to 2 y 
3 g BC powder diluted in 50 mL water, daily, orally, 
1 week 
Reduction of frequency and duration of vomit 
and diarrhoea episodes 
[22] 




One or two tablets with 200 mg of HBC powder, 
three times a day for 7 days 
Protection against the development of 
diarrhoea 
Reduction of abdominal pain complaints 
No effect on the viability of the challenge 
strains 
[67] 
Necrotizing enterocolitis 40 preterm 
piglets 
2 days of total parenteral nutrition, followed by a 
rapid transition to full enteral feeding (15 mL/kg) 
for 2 days using BC 
Lower incidence and severity of NEC in 
comparison to infant formula-fed piglets 
[68] 
34 preterm pigs Total enteral nutrition groups fed either milk 
formula, 6 h of milk formula followed by BC, or only 
BC, 15 mL/kg body weight/ 3 h. 
Increase of villi height, galactose absorption 
and brush-border enzyme activities in the 
distal small intestine 
[69] 
61 preterm pigs BC + donor human milk, 24 to 40 mL/kg/d on days 
1–2 to 120 mL/kg/d on days 3–5, enteral nutrition 
supplemented with parenteral nutrition 
Superior benefits of BC on the improvement of 
gut function, nutrient absorption, and bacterial 





BC administered as gut priming Decrease of feeding intolerance, NEC, late- 
onset sepsis and mortality 
[71] 
Drug-induced lesions 36 rats (gastric- 
induced 
damage) 
100 mice (small 
intestinal 
induced injury) 
Rat model: 2 mL BC, 25% and 50% vol/vol, oral 
administration. Indomethacin damage (20 mg/kg, 
subcutaneously) was induced 30 min after gavage 
Mouse model: drinking water supplemented with 
5% and 10% solution of BC for six days 
(approximately 5 mL/mouse/day). Indomethacin 
(85 mg/kg, subcutaneously) was administered 24 h 
before the end of the study 
Gastrointestinal restoration. Pre-treatment 
with 0.5 or 1 mL colostral preparation reduced 
gastric injury by 30% and 60%, respectively, in 
rats 
Prevented villus shortening in the mouse 
model of small intestinal injury 
[72] 
(continued on next page) 
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maintained five weeks after stopping BC supplementation, followed by 
significant weight gain. 
A placebo-controlled clinical trial with 160 children assessed the 
effect of bovine colostrum on treating acute diarrhoea [22]. For one 
week, the treated group was supplemented with commercial bovine 
colostrum product (6 g of powdered colostrum diluted in 50 mL of 
water). The authors concluded that colostrum was effective in treating 
both viral and bacterial acute diarrhoea, as they observed a reduction in 
diarrhoea and vomiting frequency and duration in the test group. Based 
on this outcome, BC should be considered as adjuvant therapy to prevent 
diarrhoea-related complications. 
Hyperimmune colostrum has also been researched for treating 
gastrointestinal disorders [67,98]. Tablets with hyperimmune colostrum 
(400 mg and 200 mg) were administered to subjects challenged with an 
enterotoxigenic E. coli (ETEC) strain. Hyperimmune bovine colostrum 
powder promoted significant protection against the development of 
diarrhoea in all treatment groups, although no antimicrobial activity 
was observed. The authors suggest that when taken before eating or 
Table 3 (continued ) 
Application Studied sample Intervention Main benefits Reference 
48 male mice Diclofenac +5% BC for 7 days, in drinking water Reduction of the increase in intestinal 
permeability induced by diclofenac, reduction 
of gut barrier dysfunction and intestinal villous 
damage 
Reduction of bacterial overgrowth 
[73] 
45 female mice Hydrolysed lactoferrin isolated from bovine 
colostrum (C-lobe) (200 mg/kg weight), orally given 
to mice submitted to NSAIDs (10 mg/kg) 
gastrointestinal damage 
Sequestration of unbound NSAIDs molecules in 
the gut, resulting in the reversal of NSAID- 
induced gastropathy 
[74] 
24 male rats BC commercial products, 2 mL (7 mg/mL), oral 
administration. Indomethacin damage (20 mg/kg, 
subcutaneously) was induced 30 min after gavage 
Restoration of gastric mucosa [15] 
37 pigs BC, busulfan plus cyclophosphamide, 11 times/ 
d (15 mL/kg), orally 
Reduction of gut toxicity during myeloablative 
chemotherapy 
Enhancement of intestinal enzyme activity 
[75] 
21 weaned pigs Mucositis induction with doxorubicin at 3.75 mg/kg. 
BC (5 mL/kg), 3 times daily, beginning the day 
before and continuing after lesion induction 
Reduction of mucositis severity in the small 
intestine 
[76] 
7 healthy male 
volunteers 
Liquid BC, 125 mL three times daily, before and after 
5 days of 50 mg of indomethacin 
No significant increase in permeability was 
seen when colostrum was co-administered 
[77]  
62 children 
1–18 years old 
Spray-dried BC powder (Biofiber-Damino™), 
7.5–30 g/ day (according to the bodyweight), 1–3 
daily doses, oral or nasogastric tube 
No difference for neutropenic fever, 
intravenous antibiotics, incidence of 
bacteremia, or intestinal mucositis 
Reduction of the peak severity of oral mucositis 
[78] 
Inflammatory bowel disease (Ulcerative 
colitis and Crohn's disease) 
Female mice BC powder (Bioversan™) (20 or 200 mg/kg/d), 
bovine Ig-enriched colostrum powder 
(Immunolac™) (20 mg/kg/d) dissolved in water. 
Oral gavage for 14 d before induction of colitis. 
Acceleration of epithelial regeneration 
Induction of immunoregulatory mechanisms 





Pure BC, BC (20 mg/kg) or colostral bovine 
lactoferrin (bLf, 150 mg/kg), 100 μL, daily, oral 
gavage, either two weeks before induction of colitis 
(prophylaxis) or after disease establishment 
(therapy) 
Whole BC prevented injury and improved the 
recovery from dextran sulfate sodium (DSS)- 
induced colitis 
[80] 
24 CD-1 mice BC powder (100 mg dissolved in 0.6 mL of saline 
solution), gastric gavage, for 7 days 
Reduction of body weight losses after TNBS- 
induced colitis 
Reduction of inflammatory markers and 
intestinal microbiota 
[81] 
24 CD-1 male 
mice 
BC powder (100 mg dissolved in 0.6 mL of saline 
solution), daily, by gavage, for 21 days 
Pre-treatment with BC promoted reduction of 
intestinal damages and clinical signs of the 
colitis 
Downregulation of toll-like receptor 4 (TLR4) 
and cytokine expression 
Stabilisation of intestinal microbiota, 




Preventive treatment: 100-500 mg/kg/day IMM- 
124E (colostrum-based product from cows 
immunized with LPS from E. coli), oral gavage, 
starting two days before colitis induction. 
Therapeutic treatment: 500 mg/kg/day IMM-124E, 
starting at day three of colitis induction. Transfer 
model colitis treatments: 25 mg/kg, 100 mg/kg, or 
500 mg/kg IMM-124E once per day. 
The hyperimmune colostrum-based product 
was effective in ameliorating colitis in the two 
different mouse models of intestinal 
inflammation 
Reduction of levels of infiltrating immune cells 
and less pronounced mucosal damage 
Enhancement of regulatory T cells and increase 
of serum levels of lipopolysaccharide [LPS]- 
binding protein 
[83] 
Short bowel syndrome 40 weaned 
female piglets 
Polymeric infant formula supplemented with bovine 
colostrum protein concentrate (13 g/kg), 8 weeks 
Increase of levels of circulating insulin-like 





Polymeric infant formula supplemented with bovine 
colostrum protein isolate (Intact™), 8 weeks 
Improvement of intestinal adaptation after 
extensive small bowel resection 
Maintenance of normal weight gain and stool 
consistency 
Enhancement of morphological adaptation 8 
weeks after surgery 
[85] 
BC: bovine colostrum; HBC: Hyperimmune bovine colostrum; ICU: intensive care unit; PBS: phosphate-buffered saline; HIV: human immunodeficiency virus; HRV: 
human rotavirus infection; NEC: necrotizing enterocolitis; NSAIDs: nonsteroidal anti-inflammatory drugs; LPS: lipopolysaccharide. 
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drinking contaminated food or drink, the hyperimmune bovine colos-
trum they obtained can protect travellers from symptomatic infection 
with ETEC [67]. 
Although the limited number of randomised controlled trials study-
ing the role of BC in infectious diarrhoea, an important systematic 
search, with meta-analysis, concluded that BC products ameliorate 
clinical symptoms of infectious diarrhoea among children [99]. 
3.3. Gut-barrier malfunction 
Non-steroidal anti-inflammatory drugs can increase intestinal 
permeability, a disorder known as “leaky gut syndrome”, increasing the 
likelihood of damage to the intestine and the risk of developing in-
flammatory and autoimmune diseases. In turn, colostrum decreases in-
testinal permeability and can be used in conjunction with non-steroidal 
anti-inflammatory drugs, preventing gastric lesions induced by these 
drugs [61]. 
Eslamian et al. evaluated enteral supplementation with bovine 
colostrum in 70 patients admitted to the ICU in a randomised, double- 
blind, placebo-controlled study [62]. The measurements of endotoxin 
and zonulin (a physiological permeability regulator) plasma levels 
showed a decrease in intestinal permeability after a short period of 
colostrum-supplemented enteral feedings. Colostrum administration 
was also effectively reduced diarrhoea in patients treated with colos-
trum, although no other secondary outcomes (vomiting, abdominal 
distention, mortality, incidence of new severe sepsis) were significantly 
different between control and treated groups. Furthermore, BC enteral 
supplementation reduced 7 days in the median length of stay in ICU 
when compared to the control group. 
Increased intestinal permeability can be excessively upregulated by 
intense physical activity; thus, it is commonly observed in elite athletes 
[100]. Hałasa and co-workers investigated the effect of colostrum 
administration on the intestinal permeability of 16 mixed martial arts 
fighters during the competitive season. They reported restoration of 
intestinal permeability to a normal limit within less than three weeks of 
relatively mild supplementation [63]. Similar results were reported in a 
double-blind crossover study when oral supplementation with 20 g/day 
of BC was given to healthy male regular exercisers for 14 days. Exercise- 
induced changes in gut permeability were reduced by approximately 
80% if colostrum had been taken. The authors postulate that this 
possibly occurs through reducing of temperature-induced apoptosis and 
inducing of heat shock protein 70 (HSP70) expression [64]. 
Cell culture experiments with four colostrum processed products 
showed that only the industrially processed ones could improve small 
intestinal barrier integrity [6]. The authors suggest that industrial pro-
cessing increased protein concentration, and treatment (ultrafiltration 
and spray-drying of pasteurised skim colostrum) possibly altered the 
protein structure, removed inhibitors, or released bioactive peptides. On 
the other hand, processing may have inactivated the active components 
capable of altering colon motility. Further in vitro and in vivo studies are 
needed, especially clinical trials with a larger number of participants 
and different clinical conditions. They will contribute to the elucidation 
of the bovine colostrum regulatory action on intestinal permeability. 
3.4. Necrotizing enterocolitis 
Necrotizing enterocolitis (NEC) is a severe gastrointestinal disease 
that mainly affects premature babies. It is related to low birth weight 
and gestational age, causing gastrointestinal complications, and leading 
to death. The action of colostrum components can be beneficial to 
developing intestinal microbiota and helping in the recovery from the 
disease [16,101]. 
The risk of NEC development in newborns is increased by a lack of 
maternal colostrum intake. A cohort study with 3420 newborn children 
found a significant association between the absence of colostrum feeding 
and the occurrence of symptoms of intestinal obstruction and neonatal 
necrotizing enterocolitis. Children who did not receive maternal colos-
trum shortly after birth were twice as likely to develop intestinal 
obstruction symptoms when compared to children in early breastfeeding 
[102]. These results reinforce the importance of maternal colostrum 
intake in the first hours of the newborn's life. The treatment of intestinal 
pediatric failure is challenging, and the early start of feeding is essential, 
being human milk the preferred choice in neonates [103]. However, 
breastfeeding is not always possible for several reasons, or the mothers' 
milk amount is not enough, which requires a well-established human 
milk bank network to process and provide human colostrum in situa-
tions where it is needed. According to Sanchez Luna et al., only a few 
milk banks are able to offer preterm human milk, colostrum and tran-
sitional preterm milk from donors [104]. 
Therefore, scientific evidence must be gathered to certify bovine 
colostrum as an alternative to prevent NEC's deadly outcomes and to 
strengthen the newborn and premature babies' immune systems, pro-
tecting them from developing other diseases. In animal experiments 
with NEC in piglets, both human milk and bovine colostrum were 
effective in maturing intestinal function, structure, and resistance 
against this severe condition [68]. Another study carried out with pre-
term pigs showed that BC effectively restored intestinal functions after 
inflammation induced by NEC [69]. 
The use of prophylactic enteral bovine colostrum in very low birth 
weight neonates was evaluated in a blinded, parallel-group, stratified, 
randomised block, placebo-controlled trial [105]. BC administration 
showed a trend toward increased stool interleukin-6 and features of 
NEC. Due to the small sample size, the authors were unable to detect 
clinical benefits. They also highlight the importance of assessing the 
safety of this treatment since BC has a large number of proteins, which 
could potentially increase intestinal inflammation. The osmolarity of BC 
was identified as an essential measurement for future studies. 
Human milk fortification with BC, also in animal experimentation, 
achieved superior performance in terms of gut function and health 
compared to formula fortification. The authors reported a reduction of 
diarrhoea and NEC incidence and modulation of gut permeability and 
cytokine levels in the human milk + BC group. BC was linked to the 
promotion of gut microbial homeostasis and preservation of barrier 
function [70]. 
In a prospective, randomised, placebo-controlled, double-blinded 
trial, 80 preterm infants were divided into two groups (BC or placebo). 
Intending to evaluate whether gut priming with bovine colostrum re-
duces nosocomial sepsis episodes, feeding intolerance and necrotizing 
enterocolitis (NEC) in premature infants, the authors concluded BC 
could be recommended for gut priming. None of the BC fed infants 
developed NEC, and significant reduction of mortality and feeding 
intolerance were registered [71]. 
Since BC could help improve the survival rate of premature babies, 
its efficacy and safety in human newborn feeding are worth more 
attention. The FortiColos multicentre study is expected to provide 
important data in this regard [106]. Even though BC composition differs 
from human colostrum, BC products could help to provide appropriate 
nutrition, especially to preterm infants who do not have access to 
breastfeeding or colostrum and milk from a human milk bank. 
3.5. Drug-induced lesions 
Anti-inflammatory drugs are widely used to treat injuries. However, 
long-term use of non-selective non-steroidal anti-inflammatory drugs 
(NSAIDs) can provoke harmful effects in the GIT [77]. More than two 
decades ago, Playford et al. demonstrated the in vitro (human colonic 
carcinoma cells HT-29) and in vivo (mice) protection conferred by 
colostrum against injuries caused by the NSAID indomethacin [72]. 
Later, in a study conducted with humans, the same research group 
evaluated healthy subjects' intestinal permeability of upon the use of 
anti-inflammatory drugs. Indomethacin increased intestinal perme-
ability by three times, while there was no increase in permeability in 
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volunteers who ingested colostrum together with the drug [77]. Mir 
et al. found that the C-terminal half of lactoferrin (C-lobe) purified from 
bovine colostrum has an affinity with NSAIDs, which can be responsible 
for the damage prevention provided by BC consumption [74]. 
Animal studies have observed comparable results. The effects of the 
combined use of colostrum with anti-inflammatory drugs to reduce 
damage in GIT was investigated in mice. A single dose of diclofenac was 
administered to induce the damage, while different colostrum pro-
portions were used to assess the protective potential against injury. As a 
result, there were decreases in intestinal permeability and damages to 
the intestinal villi and reduction of bacterial growth [73]. An important 
study conducted to compare commercially available BC products found 
beneficial effects of BC in gastric mucosa restoration, promoting cell 
proliferation and cell migration [15]. In piglets under chemotherapy, 
lower levels of inflammatory markers and greater intestinal enzyme 
activity were attributed to BC intake, which acted in reducing intestinal 
drug toxicity [75]. After another experiment using piglets, Martin and 
co-workers concluded that colostrum could be used to preventively 
reduce the damage caused by lesions from chemotherapy [76]. 
The symptoms of oral mucositis were reduced by a commercially 
available toothpaste containing lysozyme, lactoferrin, lactoperoxidase 
and colostrum purified extract. Pediatric patients with chemotherapy- 
related oral mucositis experienced significantly better oral hygiene. 
The results were attributed to BC antibacterial properties and mild anti- 
inflammatory effect (due to the antioxidant components), which 
allowed greater accuracy and tolerance to cleaning procedures as well as 
more time spent on oral hygiene [107]. 
The use of enteral supplementation with bovine colostrum was 
investigated in patients with acute lymphoblastic leukaemia and no 
beneficial effects were observed in the primary outcome (number of 
days with fever) [108]. On the other hand, the peak of oral mucositis 
severity was significantly lower in the colostrum group than in the 
placebo group, although BC administration did not diminish intestinal 
mucositis. The results suggest a possible protective effect of BC on the 
oral mucosa. 
3.6. Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is a group of diseases that affect 
the intestine, classified by two main phenotypes: ulcerative colitis and 
Crohn's disease. Its causes have not yet been clarified, but studies sug-
gest that they can be caused by intestinal mucosa immune system 
dysfunction. Hence, bovine colostrum is posed as an alternative to 
supply immune factors and growth factors, able to assist in recovering 
the GIT [16,109]. 
BC and its bioactive constituents have shown to be possibly used to 
alleviate the clinical course of inflammatory diseases, such as IBD [110]. 
An investigation about the in vitro anti-inflammatory and antibacterial 
effects of colostrum on intestinal cells showed the benefits of BC to in-
testinal health. A decrease in the inflammatory response and low bac-
terial adhesion to cells were observed [111]. 
Animal studies, using different models of induced colitis in mice, 
demonstrated that BC supplementation reduces intestinal damages. The 
prophylactic administration of BC resulted in lower clinical severity, less 
weight loss, and decreased colorectal inflammation compared to the 
control group [79]. Another study tested the effectiveness of bovine 
colostrum, immunoglobulin A and lactoferrin alone in preventing and 
treating induced colitis in mice. Mice received treatments two weeks 
before induction or after showing symptoms of the disease. Colostrum 
helped the recover from colitis after the initial injury, but there was no 
recovery of the lost weight. On the other hand, lactoferrin administra-
tion had no effect on these variables, whereas IgA improved the immune 
cell response and promoted weight gain in therapeutic treatment but did 
not improve the clinical condition [80]. 
Menchetti and coworkers observed a reduction in inflammatory 
markers and modulation of intestinal microbiota when evaluating 
bovine colostrum administration for seven days as a prophylactic mea-
sure to reduce colitis induced in mice. BC was reported to be responsible 
for stimulating the growth of Bifidobacterium spp. and Lactobacillus spp., 
considered beneficial colonic microorganisms [81]. Similar conclusions 
on the role of BC in preventing intestinal damage and signs of colitis in 
mice had been reached earlier. The study registered downregulation of 
toll-like receptor 4 (TLR4) and cytokine expression, reduction of body 
weight loss and histological score and preservation of beneficial intes-
tinal microbiota. BC administration was well tolerated and did not 
induce damages or pathological symptoms [82]. 
The use of a hyperimmune colostrum-based product was effective in 
ameliorating colitis in two mechanistically different mouse models of 
intestinal inflammation [83]. The mechanism of action of the bioactive 
components remains unknown, but it might be related to the formation 
of immune complexes of IgG with microbial lipopolysaccharides, 
reducing the inflammatory responses. The authors suggest the hyper-
immune colostrum-based product might be a promising novel thera-
peutic agent in IBD, to be used alone, for maintaining remission in mild 
colitis cases, or combined with other treatments, aiming to enhance the 
therapeutic efficacy. 
The potential beneficial effects of BC on inflammatory bowel dis-
eases must be investigated with randomised placebo-controlled clinical 
trials. Well-designed studies will help to draft conclusions regarding BC 
application as a treatment for these conditions. They will provide a 
better understanding of which BC components modulate the inflam-
matory process and could subside the development of administration 
protocols, appropriate for each type of disease, according to the patients' 
clinical status. Potential contraindications also need to be studied. 
3.7. Short bowel syndrome 
Short bowel syndrome is an intestinal insufficiency resulting from 
intestine resection due to infarction of the mesenteric vessels, trauma, 
abnormalities, or complications of Crohn's disease. It is characterised by 
diarrhoea and low nutrient absorption, with consequent malnutrition 
and weight loss [112]. 
Pereira-Fantini and co-workers obtained promising results when 
analysing colostrum protein concentrate supplementation in piglets. 
Supplementation resulted in muscle hypertrophy, increased levels of 
circulating insulin-like growth factor (IGF-1) and binding proteins. The 
findings indicate that supplementation with colostrum protein concen-
trate may be an alternative for treating short bowel syndrome [84]. 
Although no evidence of small bowel adaptation when using a diet with 
IGF-1 enriched colostrum in piglets was found [113], normal weight 
gain and stool normalisation were observed in animals with massive 
small bowel resection when treated with colostrum protein concentrate. 
Increased villus length and crypt depth in intestinal epithelium are 
morphological features of intestinal adaptation, which was improved by 
BC protein concentrate supplementation [85]. 
Conversely, clinical trials found no differences in colostrum admin-
istration compared to placebo in patients with short bowel syndrome 
[114,115]. Considering that both studies were carried out with a very 
small population (twelve and nine volunteers), further research is 
needed to investigate the effect of BC in short bowel syndrome symp-
toms in humans and confirm the results reported so far. The potential 
benefits of BC or its isolated bioactive compounds in short bowel syn-
drome treatment remain uncertain. 
4. Conclusion 
Bovine colostrum has a unique combination of nutrients and bioac-
tive compounds, making it a natural supplement or source of molecules 
for high added-value nutraceutical foods and products. BC intake can 
improve gastrointestinal symptoms related to several disorders and 
diseases thank important attributes, such as protection against patho-
genic microbial growth, enhancement of beneficial microbiota, 
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reduction of endotoxemia, modulation of the immune response, stimu-
lation of growth and repair of damaged intestinal tissues and restoration 
of gut permeability. Therefore, BC consumption might be a valuable 
prevention factor or treatment for various conditions where gastroin-
testinal tract function is impaired. 
Although there is evidence of the role of BC in maintaining and 
restoring intestinal health, further investigations should be focused on 
better understanding the mechanisms of action involved in the protec-
tive effect of bovine colostrum on the gastrointestinal tract. Moreover, 
monitoring the industrial-scale processing methods is essential to pre-
serve the integrity of the biologically active molecules in BC products. 
These molecules have been reported as the key for the unique properties 
of BC therefore, the influence of gastrointestinal environment conditions 
and interaction with intestinal microbiota may drastically change BC 
efficacy according to the amount and form of administration. Future 
investigations must be carried out in this direction since the physiopa-
thology of GIT disorders is very distinct, which requires different ther-
apeutic and/or preventive approaches. 
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[45] A. Akbache, É. Lamiot, O. Moroni, S. Turgeon, S.F. Gauthier, Y. Pouliot, Use of 
membrane processing to concentrate TGF-β2 and IGF-I from bovine milk and 
whey, J. Membr. Sci. 326 (2009), https://doi.org/10.1016/j. 
memsci.2008.10.026. 
[46] M. Fernández, J.A. Hudson, R. Korpela, C.G. De Los Reyes-Gavilán, Impact on 
human health of microorganisms present in fermented dairy products: an 
overview, Biomed. Res. Int. 2015 (2015), https://doi.org/10.1155/2015/ 
412714. 
[47] M. García-Burgos, J. Moreno-Fernández, M.J.M. Alférez, J. Díaz-Castro, I. López- 
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